Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical and Takeda Bio Development Center have submitted a new drug application of anti-cancer agent, panitumumab for the treatment of patients with progressed or relapse colorectal cancer to the Ministry of Health Labour and Welfare in Japan.
Subscribe to our email newsletter
Panitumumab is a fully-human monoclonal antibody which binds to epidermal growth factor receptor and suppresses tumor growth. It shows a low incidence of allergic reaction upon and also after administration as it is a fully-human monoclonal antibody.
Masaomi Miyamoto, general manager of pharmaceutical development division of Takeda, said: “We expect to offer panitumumab as early as possible to the patients with colorectal cancer, which is increasing in number in Japan, and healthcare providers, as a new treatment option different from existing chemotherapies.”